We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 22, 2022

First-Line Osimertinib for NSCLC With Uncommon EGFR Mutations

Journal of Thoracic Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN)
J Thorac Oncol 2022 Oct 25;[EPub Ahead of Print], J Bar, N Peled, S Schokrpur, M Wolner, O Rotem, N Girard, FA Nana, S Derijcke, W Kian, S Patel, H Gantz-Sorotsky, A Zer, M Moskovitz, G Metro, Y Rottenberg, A Calles, M Hochmair, K Cuppens, L Decoster, M Reck, D Limon, E Rodriguez, C Astaras, A Bettini, S Häfliger, A Addeo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading